Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Integral Diagnostics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Integral Diagnostics şirketinin kazançları yıllık ortalama -47.6% oranında azalırken, Healthcare sektörünün kazançları yıllık 3.3% oranında azalan oldu. Gelirler yıllık ortalama 13.8% oranında artan oldu.

Anahtar bilgiler

-47.6%

Kazanç büyüme oranı

-48.7%

EPS büyüme oranı

Healthcare Sektör Büyümesi	2.4%
Gelir büyüme oranı	13.8%
Özkaynak getirisi	-20.1%
Net Marj	-12.9%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Integral Diagnostics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:IDX Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	470	-61	27	15
31 Mar 24	463	-59	26	14
31 Dec 23	456	-58	26	0
30 Sep 23	449	-16	26	0
30 Jun 23	441	25	25	13
31 Mar 23	418	23	24	6
31 Dec 22	395	21	22	0
30 Sep 22	378	18	21	0
30 Jun 22	361	15	21	0
31 Mar 22	361	18	21	0
31 Dec 21	360	22	22	0
30 Sep 21	356	26	22	0
30 Jun 21	351	31	22	0
31 Mar 21	333	32	21	0
31 Dec 20	315	32	19	0
30 Sep 20	295	28	18	0
30 Jun 20	276	23	16	0
31 Mar 20	263	22	18	0
31 Dec 19	250	21	19	0
30 Sep 19	241	21	21	0
30 Jun 19	232	21	24	0
31 Mar 19	222	19	23	0
31 Dec 18	211	17	23	0
30 Sep 18	200	16	22	0
30 Jun 18	189	15	21	0
31 Mar 18	187	15	21	0
31 Dec 17	185	15	20	0
30 Sep 17	182	15	20	0
30 Jun 17	180	15	20	0
31 Mar 17	177	16	19	0
31 Dec 16	175	16	19	0
30 Sep 16	171	14	18	0
30 Jun 16	168	11	18	0
31 Mar 16	165	11	17	0
31 Dec 15	162	11	17	0
30 Sep 15	157	8	17	0
30 Jun 15	151	5	16	0
30 Jun 14	4	3	1	0

Kaliteli Kazançlar: IDX şu anda kârlı değil.

Büyüyen Kar Marjı: IDX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IDX kârlı değildir ve zararlar son 5 yılda yılda 47.6% oranında artmıştır.

Büyüme Hızlandırma: IDX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IDX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( -25.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IDX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -20.12% ) sahiptir.

Integral Diagnostics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023)

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Recent updates

Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023)

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin